May 9, 2022 01:51 PM EDT
Pharma
Marketing

Deep­In­tent ponies up ad guar­an­tees to take the edge off phar­mas' pro­gram­mat­ic ad hes­i­ta­tion

Beth Snyder Bulik

Senior Editor

Phar­ma com­pa­nies still lag oth­er in­dus­tries when it comes to pro­gram­mat­ic ad­ver­tis­ing use, but the promise of bet­ter tar­get­ing – and now ad guar­an­tees …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times